These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 10846597)
21. HIV resistance testing proves its value. Proj Inf Perspect; 1999 Sep; (28):14. PubMed ID: 11367356 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. Holguín A; Ramirez de Arellano E; Rivas P; Soriano V AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277 [TBL] [Abstract][Full Text] [Related]
23. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection. Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760 [TBL] [Abstract][Full Text] [Related]
24. Resistance tests: what do clinical trials tell us? Price N; Smit E; Pillay D J HIV Ther; 2002 Nov; 7(4):80-6. PubMed ID: 12733605 [TBL] [Abstract][Full Text] [Related]
25. The use of resistance testing in the management of HIV-1-infected patients. Grant PM; Zolopa AR Curr Opin HIV AIDS; 2009 Nov; 4(6):474-80. PubMed ID: 20048713 [TBL] [Abstract][Full Text] [Related]
26. Understanding transmitted HIV resistance through the experience in the USA. Taiwo B Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289 [TBL] [Abstract][Full Text] [Related]
27. Interpretation of resistance assay results. Miller V Antivir Ther; 2001; 6 Suppl 2():1-9. PubMed ID: 11678473 [No Abstract] [Full Text] [Related]
28. Opinion paper. Resistance to new anti-HIV agents: problems in the pathway of drug registration. Dalmau D; Klimkait T; Telenti A Antivir Ther; 2005; 10(7):867-72. PubMed ID: 16312184 [TBL] [Abstract][Full Text] [Related]
29. Antiretroviral resistance. Geretti AM J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209 [No Abstract] [Full Text] [Related]
30. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064 [TBL] [Abstract][Full Text] [Related]
32. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James. Feigal D AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399 [TBL] [Abstract][Full Text] [Related]
33. Study on mutations and antiretroviral therapy (SMART): preliminary results. Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873 [TBL] [Abstract][Full Text] [Related]
34. Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy. Schmidt B; Walter H; Zeitler N; Korn K AIDS Rev; 2002; 4(3):148-56. PubMed ID: 12416449 [TBL] [Abstract][Full Text] [Related]